Tumor immunology is the investigation of how the immune system responds to cancer cells and how these responses can be leveraged for successful treatments. The topic "Tumor Immunology" emphasizes an understanding of immune responses against tumors and the creation of therapies that turn on or augment the body's natural defenses.".
Cancer cells may avoid immune elimination by downregulating immune activation or inducing an immunosuppressive microenvironment. This session discusses how scientists recognize such mechanisms and engineer countermeasures against them. Major subjects are checkpoint inhibitors, adoptive cell therapies, cytokine-based interventions, and tumor vaccines. Elucidation of the immune microenvironment is fundamental in being able to predict patient outcomes and advance therapeutic outcome.
The session also features progress in immunotherapy and combination approaches that combine immune-based therapies with chemotherapy, radiation, or targeted agents. New research in biomarkers and immune profiling is facilitating more individualized approaches, so that therapies are personalized to each patient's tumor type.
Participants will learn about the biology of tumor-immune interactions, clinical use of immunotherapy, and research that is defining oncology's future. This session highlights the immune system's pivotal role in cancer management and the promise of tumor immunology to transform patient care.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
